Your shopping cart is currently empty

LSD1-IN-31 (compound 11e) interacts directly with the LSD1/CoREST complex, inhibiting the demethylase activity of LSD1. This inhibition of LSD1 demethylase activity impacts the downstream IκB/NF-κB signaling pathway. Furthermore, LSD1-IN-31 can inhibit osteoclast-mediated bone loss both in vitro and in vivo. This compound is utilized in research on osteoporosis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | LSD1-IN-31 (compound 11e) interacts directly with the LSD1/CoREST complex, inhibiting the demethylase activity of LSD1. This inhibition of LSD1 demethylase activity impacts the downstream IκB/NF-κB signaling pathway. Furthermore, LSD1-IN-31 can inhibit osteoclast-mediated bone loss both in vitro and in vivo. This compound is utilized in research on osteoporosis. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.